Common Variants at 9p21 and 8q22 Are Associated with Increased Susceptibility to Optic Nerve Degeneration in Glaucoma

Janey L. Wiggs, Brian L. Yaspan, Michael A. Hauser, Jae H. Kang, R. Rand Allingham, Lana M. Olson, Wael Abdrabou, Baojian Fan, Dan Y. Wang, Wendy Brodeur, Donald L. Budenz, Joseph Caprioli, Andrew Crenshaw, Kristy Crooks, E. DelBono, Kimberly F. Doheny, David S. Friedman, Douglas Gaasterland, Terry Gaasterland, Cathy C. Laurie, Richard K. Lee, Paul R. Lichter, Stephanie Loomis, Yutao Liu, Felipe A. Medeiros, Cathy McCarty, Daniel B. Mirel, Sayoko E. Moroi, David C. Musch, Anthony Realini, Frank W. Rozsa, Joel S. Schuman, Kathleen M. Scott, Kuldev Singh, Joshua D. Stein, Edward H. Trager, Paul VanVeldhuisen, Douglas Vollrath, Gadi Wollstein, Sachiko Yoneyama, Kang Zhang, Robert N. Weinreb, Jason Ernst, Manolis Kellis, Tomohiro Masuda, Donald J. Zack, Julia E. Richards, Margaret A. Pericak‐Vance, Louis R. Pasquale, Jonathan L. HainesPLoS 2012 · DOI · OpenAlex

Abstract

Optic nerve degeneration caused by glaucoma is a leading cause of blindness worldwide. Patients affected by the normal-pressure form of glaucoma are more likely to harbor risk alleles for glaucoma-related optic nerve disease. We have performed a meta-analysis of two independent genome-wide association studies for primary open angle glaucoma (POAG) followed by a normal-pressure glaucoma (NPG, defined by intraocular pressure (IOP) less than 22 mmHg) subgroup analysis. The overall meta-analysis of the GLAUGEN and NEIGHBOR dataset results (3,146 cases and 3,487 controls) identified significant associations between two loci and POAG: the CDKN2BAS region on 9p21 (rs2157719 [G], OR = 0.69 [95%CI 0.63-0.75], p = 1.86×10⁻¹⁸), and the SIX1/SIX6 region on chromosome 14q23 (rs10483727 [A], OR = 1.32 [95%CI 1.21-1.43], p = 3.87×10⁻¹¹). In sub-group analysis two loci were significantly associated with NPG: 9p21 containing the CDKN2BAS gene (rs2157719 [G], OR = 0.58 [95% CI 0.50-0.67], p = 1.17×10⁻¹²) and a probable regulatory region on 8q22 (rs284489 [G], OR = 0.62 [95% CI 0.53-0.72], p = 8.88×10⁻¹⁰). Both NPG loci were also nominally associated with a second type of glaucoma, exfoliation syndrome glaucoma, suggesting that these loci might contribute more generally to optic nerve degeneration in glaucoma. Because both loci influence transforming growth factor beta (TGF-beta) signaling, we performed a genomic pathway analysis that showed an association between the TGF-beta pathway and NPG (permuted p = 0.009). These results suggest that neuro-protective therapies targeting TGF-beta signaling could be effective for multiple forms of glaucoma.

Introduction

Glaucoma is a leading cause of irreversible blindness, characterized by the progressive death of retinal ganglion cells and subsequent optic nerve degeneration. While medical intervention traditionally focuses on managing intraocular pressure (IOP), a significant portion of patients—at least 33%—suffer from Normal-Pressure Glaucoma (NPG). In these cases, the optic nerve continues to degenerate despite "normal" eye pressure levels. Current treatments are effective at lowering pressure but lack "neuroprotective" capabilities to stop nerve death directly. This study aims to identify genetic variants that increase the optic nerve's vulnerability to damage independent of IOP, potentially uncovering new biological targets for treatment.

Methodology

The researchers employed a multi-stage genomic approach to isolate variants related to nerve vulnerability:

  1. Meta-Analysis: Data from two large independent GWAS datasets, GLAUGEN (Glaucoma Genes and Environment) and NEIGHBOR (NEI Glaucoma Human genetics collaBORation), were combined. The total meta-analysis included 3,146 cases and 3,487 controls of European ancestry.
  2. Subgroup Analysis: Patients were categorized into NPG (IOP < 22 mmHg) and High-Pressure Glaucoma (HPG) to distinguish between pressure-related and pressure-independent risk factors.
  3. Pathway Analysis: The PARIS (Pathway Analysis by Randomization Incorporating Structure) algorithm was used to determine if associated genes clustered into specific biological pathways.
  4. Functional Validation: RT-PCR and laser microdissection were performed on human and mouse ocular tissues to confirm gene expression in the optic nerve and retina.

Key Results

Identification of "Nerve Vulnerability" Loci

The meta-analysis confirmed the significance of the 9p21 region (containing CDKN2BAS) and identified a novel region on 8q22.

  • POAG Overall: Strong associations were found at 9p21 (CDKN2BAS, $p = 1.86 \times 10^{-18}$) and 14q23 (SIX1/SIX6, $p = 3.87 \times 10^{-11}$).
  • NPG Subgroup: The 9p21 locus showed a more pronounced effect in the normal-pressure group ($OR = 0.58, p = 1.17 \times 10^{-12}$). Crucially, the 8q22 region reached genome-wide significance specifically in this subgroup ($OR = 0.62, p = 8.88 \times 10^{-10}$).

The TGF-Beta Signaling Pathway

A central finding was that both the 9p21 and 8q22 loci influence Transforming Growth Factor beta (TGF-beta) signaling. This pathway is a known regulator of cell growth and apoptosis. Pathway analysis revealed a significant association ($p = 0.009$) between NPG and the TGF-beta pathway, suggesting it is a critical driver of optic nerve death.

Localization and Cross-Disease Relevance

The 8q22 association is located in a "gene desert," likely acting as a regulatory switch for nearby genes LRP12 and ZFPM2. RT-PCR confirmed that these genes are expressed in the human optic nerve and the retinal ganglion cell layer. Furthermore, risk alleles for NPG were also associated with exfoliation glaucoma, indicating a shared biological mechanism of nerve death across different glaucoma subtypes.

Discussion

While this study provides a robust genetic roadmap for understanding optic nerve degeneration, several limitations remain. The NPG subgroup size (720 cases) is relatively small for a GWAS, and the study focused exclusively on populations of European ancestry. Additionally, the exact molecular mechanisms by which these variants trigger nerve death require further exploration in animal models.

The identification of the TGF-beta pathway as a key player opens the door for developing neuroprotective therapies. By targeting this pathway directly, clinicians may eventually be able to prevent blindness in patients for whom pressure-lowering treatments are insufficient.

Summary updated

Abstract

Optic nerve degeneration caused by glaucoma is a leading cause of blindness worldwide. Patients affected by the normal-pressure form of glaucoma are more likely to harbor risk alleles for glaucoma-related optic nerve disease. We have performed a meta-analysis of two independent genome-wide association studies for primary open angle glaucoma (POAG) followed by a normal-pressure glaucoma (NPG, defined by intraocular pressure (IOP) less than 22 mmHg) subgroup analysis. The single-nucleotide polymorphisms that showed the most significant associations were tested for association with a second form of glaucoma, exfoliation-syndrome glaucoma. The overall meta-analysis of the GLAUGEN and NEIGHBOR dataset results (3,146 cases and 3,487 controls) identified significant associations between two loci and POAG: the CDKN2BAS region on 9p21 (rs2157719 [G], OR = 0.69 [95%CI 0.63-0.75], p = 1.86×10⁻¹⁸), and the SIX1/SIX6 region on chromosome 14q23 (rs10483727 [A], OR = 1.32 [95%CI 1.21-1.43], p = 3.87×10⁻¹¹). In sub-group analysis two loci were significantly associated with NPG: 9p21 containing the CDKN2BAS gene (rs2157719 [G], OR = 0.58 [95% CI 0.50-0.67], p = 1.17×10⁻¹²) and a probable regulatory region on 8q22 (rs284489 [G], OR = 0.62 [95% CI 0.53-0.72], p = 8.88×10⁻¹⁰). Both NPG loci were also nominally associated with a second type of glaucoma, exfoliation syndrome glaucoma (rs2157719 [G], OR = 0.59 [95% CI 0.41-0.87], p = 0.004 and rs284489 [G], OR = 0.76 [95% CI 0.54-1.06], p = 0.021), suggesting that these loci might contribute more generally to optic nerve degeneration in glaucoma. Because both loci influence transforming growth factor beta (TGF-beta) signaling, we performed a genomic pathway analysis that showed an association between the TGF-beta pathway and NPG (permuted p = 0.009). These results suggest that neuro-protective therapies targeting TGF-beta signaling could be effective for multiple forms of glaucoma.
BibTeX
@inproceedings{wiggs2012common,
  author = {Janey L. Wiggs and Brian L. Yaspan and Michael A. Hauser and Jae H. Kang and R. Rand Allingham and Lana M. Olson and Wael Abdrabou and Baojian Fan and Dan Y. Wang and Wendy Brodeur and Donald L. Budenz and Joseph Caprioli and Andrew Crenshaw and Kristy Crooks and E. DelBono and Kimberly F. Doheny and David S. Friedman and Douglas Gaasterland and Terry Gaasterland and Cathy C. Laurie and Richard K. Lee and Paul R. Lichter and Stephanie Loomis and Yutao Liu and Felipe A. Medeiros and Cathy McCarty and Daniel B. Mirel and Sayoko E. Moroi and David C. Musch and Anthony Realini and Frank W. Rozsa and Joel S. Schuman and Kathleen M. Scott and Kuldev Singh and Joshua D. Stein and Edward H. Trager and Paul VanVeldhuisen and Douglas Vollrath and Gadi Wollstein and Sachiko Yoneyama and Kang Zhang and Robert N. Weinreb and Jason Ernst and Manolis Kellis and Tomohiro Masuda and Donald J. Zack and Julia E. Richards and Margaret A. Pericak‐Vance and Louis R. Pasquale and Jonathan L. Haines},
  title = {{Common Variants at 9p21 and 8q22 Are Associated with Increased Susceptibility to Optic Nerve Degeneration in Glaucoma}},
  booktitle = {PLoS},
  year = {2012},
  doi = {10.1371/journal.pgen.1002654},
}
Figure